NEW MJ NEWS

AbbVie to Present at the Morgan Stanley Healthcare Conference

AbbVie (NYSE: ABBV) will participate in the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, September 13, 2022. Rob Michael, vice chairman and president, Jeff Stewart, executive vice president, commercial operations, and Neil Gallagher, vice president development and chief medical officer will present at 9:35 a.m. Central time.

A live audio webcast of the presentation will be accessible through AbbVie’s Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.

About AbbVie

AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn.

View original content:https://www.prnewswire.com/news-releases/abbvie-to-present-at-the-morgan-stanley-healthcare-conference-301618670.html

SOURCE AbbVie


MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

$GWPH Appoints Senior Industry Executive to President, North America

GW Appoints Senior Industry Executive to President, North America and Relocates CEO…

InMed Pharmaceuticals Inc. (IMLFF) Files PCT Patent Application for the Treatment of Pain with Cannabinoids

InMed Pharmaceuticals Files PCT Patent Application for the Treatment of Pain with…

InMed Pharmaceuticals Inc. (IMLFF) Dr. Vikramaditya G. Yadav to Scientific Advisory Board

InMed Appoints Dr. Vikramaditya G. Yadav to Scientific Advisory Board InMed Pharmaceuticals…